IMARC Group, a leading market research company, has recently releases report titled “Non-Alcoholic Steatohepatitis (NASH) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global non-alcoholic steatohepatitis (NASH) market size, share, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights
How big is the non-alcoholic steatohepatitis (NASH) market?
The global non-alcoholic steatohepatitis (NASH) market size reached US$ 1.21 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.55 Billion by 2028, exhibiting a growth rate (CAGR) of 27.70% during 2023-2028.
What is non-alcoholic steatohepatitis (NASH)?
Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD) that progresses over time caused by overweight, insulin resistance, and metabolic syndrome. Its symptoms include weight loss, jaundice, itchy skin, fatigue, weakness, spider veins, an enlarged liver, difficulty concentrating, fluid accumulation, and abdominal discomforts, such as pain and swelling. It is also diagnosed with several techniques, including liver biopsy, magnetic resonance imaging (MRI), ultrasound, physical examination, blood tests, and computed tomography (CT) scans.
The treatment for NASH involves liver transplants, medication, and numerous lifestyle modifications such as a healthy diet and regular exercise. These treatment methods can improve liver function, reduce inflammation, reduce liver fat accumulation, and minimize liver damage. Additionally, they improve long-term outcomes, enhance patients' quality of life, and can help manage other health issues such as obesity and high blood pressure. Consequently, non-alcoholic steatohepatitis (NASH) finds applications in online, hospital, and retail pharmacies across the globe.
Request for a free sample copy of this report: https://www.imarcgroup.com/non-alcoholic-steatohepatitis-market/requestsample
What are the growth prospects and trends in the non-alcoholic steatohepatitis (NASH)?
The market is primarily driven by the increasing occurrences of NASH due to sedentary lifestyles, genetics, unhealthy eating habits, high calories intakes of processed food, obesity, and type 2 diabetes. Additionally, the rising demand for NASH treatments to prevent premature death, alleviate symptoms, increase lifespan, and promote the overall well-being of patients are contributing to market growth. In line with this, the growing awareness among individuals regarding the early diagnosis and treatment of NASH is helping to minimize healthcare expenses, eliminate the need for liver transplants, and prevent future complications such as high blood pressure, cardiovascular diseases (CVDs), cancer, cirrhosis, and liver failure which is influencing the market growth.
Moreover, continuous technological development and the integration of artificial intelligence (AI) and machine learning (ML) to improve diagnosis accuracy, predict disease progression, and develop personalized treatments represent another major growth-inducing factor. Besides this, the extensive use of non-invasive imaging techniques such as magnetic resonance imaging (MRI) and transient elastography (TE) to monitor and diagnose NASH while enhancing patient comfort, lowering the risk of complications, increasing compliance, and improving clinical outcomes are accelerating product adoption rates. Along with this, various governments are taking initiatives to provide access to high-quality treatment and support the development of advanced therapeutics, thus providing a positive thrust to market growth.
Apart from this, the non-alcoholic steatohepatitis (NASH) market is growing at different rates in numerous regions, with the North America region being one of the largest non-alcoholic steatohepatitis (NASH) markets due to the increasing prevalence of NASH, rising government initiatives, and several technological advancements. Moreover, the industry is expected to face competition in the coming years as various key players are implementing competitive strategies to sustain their presence in the market. For instance, in April 2019, Gilead Sciences Inc. established a strategic partnership with Insitro to develop novel therapies for non-alcoholic steatohepatitis, where Gilead Sciences Inc. is leveraging Insitro's proprietary drug development platform. Furthermore, the growing geriatric population, increasing healthcare expenditure, extensive research and development (R&D) activities, significant growth in the healthcare industry, and rising demand for non-invasive treatment options are creating a positive market outlook across the globe.
What is included in market segmentation?
The report has segmented the market into the following categories:
Drug Type Insights:
- Vitamin E and Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cenicriviroc
- Others
Disease Cause Insights:
- Hypertension
- Heart Disease
- High Blood Lipid
- Type 2 Diabetes
- Obesity
Sales Channel Insights:
- Hospital Pharmacy
- Online Providers
- Retail Pharmacy
End User Insights:
- Hospitals
- Clinics
- Homecare Settings
Breakup by Geography:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
- Algernon Pharmaceuticals
- Galmed Pharmaceuticals Ltd
- Intercept Pharmaceuticals Inc.
- Zydus Lifesciences Limited
Ask Analyst for Customization and Browse full report with TOC & List of Figure: https://www.imarcgroup.com/request?type=report&id=7397&flag=C
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/